Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have earned a consensus rating of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $8.50.

ANRO has been the topic of several analyst reports. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Alto Neuroscience in a research report on Monday, August 18th. Wedbush reiterated a “neutral” rating and issued a $4.00 target price on shares of Alto Neuroscience in a research report on Thursday, May 15th.

Hedge Funds Weigh In On Alto Neuroscience

Institutional investors and hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN raised its stake in Alto Neuroscience by 40.0% during the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock worth $46,000 after purchasing an additional 3,139 shares during the period. Deutsche Bank AG raised its stake in Alto Neuroscience by 31.3% during the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock worth $64,000 after purchasing an additional 3,629 shares during the period. Jane Street Group LLC raised its stake in Alto Neuroscience by 72.0% during the fourth quarter. Jane Street Group LLC now owns 18,600 shares of the company’s stock worth $79,000 after purchasing an additional 7,783 shares during the period. AlphaCore Capital LLC raised its stake in Alto Neuroscience by 100.0% during the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after purchasing an additional 10,000 shares during the period. Finally, Barclays PLC raised its stake in Alto Neuroscience by 34.5% during the fourth quarter. Barclays PLC now owns 39,807 shares of the company’s stock worth $168,000 after purchasing an additional 10,208 shares during the period.

Alto Neuroscience Trading Up 8.8%

NYSE ANRO opened at $3.9070 on Monday. The company has a current ratio of 18.43, a quick ratio of 18.43 and a debt-to-equity ratio of 0.18. The company has a fifty day simple moving average of $2.80 and a two-hundred day simple moving average of $2.70. Alto Neuroscience has a 12-month low of $1.60 and a 12-month high of $15.04. The stock has a market cap of $105.80 million, a P/E ratio of -1.63 and a beta of 1.84.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Wednesday, August 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08). On average, analysts forecast that Alto Neuroscience will post -2.54 earnings per share for the current year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.